Spontaneous Reproductive Outcomes After Oral Inositol Supplementation in Infertile Polycystic Ovarian Syndrome Women.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-01-01

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Polycystic ovarian syndrome (PCOS) is a heterogeneous, multifaceted and complex disorder characterized by insulin resistance (IR), hyperinsulinemia, and hyperandrogenism leading ovarian disfunction and infertility. Given the central pathogenic role of IR in the endocrine, reproductive, and metabolic disturbances of PCOS, several pharmacological and non-pharmacological approaches have been proposed to counteract the hyper insulinemic IR typical of the syndrome. Two Inositol stereoisomers, Myo-Inositol (MI) and D-chiro-inositol (DCI), captured the attention of researchers for their insulin-sensitizing actions, which configure them as proper candidates for the treatment of PCOS.

Very few studies reported on spontaneous clinical pregnancy rates, none were powered for this outcome, and none reported on the clinically relevant outcome of live birth. Therefore, data about clinical pregnancy rate, live birth rate, and miscarriage rate comparing inositols with placebo are limited.

Conversely, about infertility and assisted reproduction techniques (ART), improvements have been reported in PCOS women who underwent fertility treatment using inositol in different forms, combinations or doses. This data, considering the different tissue-specific ratios (i.e., 100:1 in the ovary) and the different physiological roles of inositol stereoisomers, suggest that DCI supplementation alone might not be the optimal or appropriate approach for improving IVF outcomes in PCOS patients, and drawn attention to the importance of MI and DCI supplementation in a physiological ratio in order to restore normal ovary functionality. Indeed, the combination of MI and DCI, at a more physiological ratio of 40:1, was able to more quickly restore to normal the hormonal and metabolic parameters in PCOS women than MI treatment alone or DCI treatment alone, improving the endocrine profile and IR of women with PCOS.

Nevertheless, regarding infertility the primary outcomes that should be considered are clinical pregnancy rate, miscarriage rate and live birth rate. Although many studies showed improved hormonal and metabolic profile and improved ovulation rate and higher quality and number of oocyte retrieved in ART in PCOS women after inositols administration, data about clinical pregnancy rate, live birth rate, and miscarriage rate are limited with several concerns regarding interpretation of the studies.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Oral Inositol Supplementation on Obstetrics Outcomes in PCOS Women

NCT03585738

Polycystic Ovary Syndrome

NOT_YET_RECRUITING NA

Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients

NCT01246310

Depression PCOS

TERMINATED NA

Interest of Myo-inositol Supplementation in Women With Polycystic Ovarian Syndrome

NCT03059173

Polycystic Ovary Syndrome Reproductive Medicine

RECRUITING PHASE3

Could the Therapy With Inositol Affect the Cardiovascular Risk in PCOS Women? Results of a Randomized Clinical Trial

NCT01574261

Polycystic Ovary Syndrome

UNKNOWN EARLY_PHASE1

Inositol Treatment in Different Type of PCOS Phenotype

NCT05678114

Polycystic Ovary Syndrome

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Polycystic Ovarian Syndrome Infertility, Female

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized multi centre double-blind controlled trial

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

The patients, care provides, investigators and outcome assessors are blinded for the treatment: Inositol + Folic acid versus Folic acid alone. The treatment allocation is identified by code number before the study start, and will be revealed only after data analysis.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Inositol + Folic acid

Couples with PCOS infertile women, diagnosed according to the Rotterdam criteria, who access infertility center with conception desire. These women will receive oral supplementation with Inositol (Myo-inositol and D-chiro-inositol at 40:1 ratio) plus Folic acid for 6 months.

Couples are required to have regular intercourse with the aim to achieve a spontaneous conception.

Group Type EXPERIMENTAL

Inositol + Folic acid

Intervention Type DIETARY_SUPPLEMENT

Daily oral supplementation of for 6 months or until pregnancy conception:

Myo-Inositol: 1100 mg D-chiro-inositol: 27.6 mg Folic acid: 400 mcg

Regular intercourses

Intervention Type BEHAVIORAL

Couples are required to have regular intercourses with the aim to achieve a spontaneous conception.

Folic acid

Couples with PCOS infertile women, diagnosed according to the Rotterdam criteria, who access infertility center with conception desire. These women will receive oral supplementation with Folic acid for 6 months.

Couples are required to have regular intercourse with the aim to achieve a spontaneous conception.

Group Type PLACEBO_COMPARATOR

Folic acid

Intervention Type DIETARY_SUPPLEMENT

Daily oral supplementation of for 6 months:

Folic acid: 400 mcg

Regular intercourses

Intervention Type BEHAVIORAL

Couples are required to have regular intercourses with the aim to achieve a spontaneous conception.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Inositol + Folic acid

Daily oral supplementation of for 6 months or until pregnancy conception:

Myo-Inositol: 1100 mg D-chiro-inositol: 27.6 mg Folic acid: 400 mcg

Intervention Type DIETARY_SUPPLEMENT

Folic acid

Daily oral supplementation of for 6 months:

Folic acid: 400 mcg

Intervention Type DIETARY_SUPPLEMENT

Regular intercourses

Couples are required to have regular intercourses with the aim to achieve a spontaneous conception.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women with PCOS diagnosed by Rotterdam criteria in couple that desire to conceive.

Exclusion Criteria

* Male infertility factor that require in vitro fertilization technique.
* Women with infertility factors that require in vitro fertilization technique.
* Couple with infertility factors that require in vitro fertilization technique.
* Diabetes mellitus that require insulin or oral drugs treatment.
* Any other pre-pregnancy or pregnancy-induced/related disease.
* Any other pharmacological, non-pharmacological or nutraceutical treatment (beside oral folic acid supplementation) more than 3 months before the enrollment (wash-out period) or during the trial.

Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes